T. Rowe Price Investment Management’s Axsome Therapeutics AXSM Stock Holding History

T. Rowe Price Investment Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.31M	Sell	13,643 -2	-0%	-$345	﹤0.01%	592
2025 Q4	$2.49M	Sell	13,645 -260,369	-95%	-$36.3M	﹤0.01%	612
2025 Q3	$33.3M	Buy	274,014 +25,288	+10%	+$2.85M	0.02%	440
2025 Q2	$26M	Sell	248,726 -18,271	-7%	-$1.93M	0.02%	471
2025 Q1	$31.1M	Buy	+266,997	New	+$30.4M	0.02%	468

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management's AXSM Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Axsome Therapeutics (AXSM) stake by 0.01% in Q1 2026, selling an estimated $345 and leaving 13,643 shares worth $2.31M. The position accounts for ﹤0.01% of the portfolio, ranked #592.

T. Rowe Price Investment Management first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $33.3M in Q3 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

T. Rowe Price Investment Management held 13,643 shares of Axsome Therapeutics worth $2.31M as of Q1 2026.
T. Rowe Price Investment Management sold 2 Axsome Therapeutics shares in Q1 2026, an estimated $345.
Axsome Therapeutics made up ﹤0.01% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #592 holding.
T. Rowe Price Investment Management first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
T. Rowe Price Investment Management's Axsome Therapeutics position peaked at $33.3M in Q3 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.